Radu O. Minea, MD

Assistant Professor of Research Neurological Surgery

Image of Radu O. Minea, MD
Is this your profile? Click to edit

Publications

  • Activation of Epstein-Barr Virus’ Lytic Cycle in Nasopharyngeal Carcinoma Cells by NEO212, a Conjugate of Perillyl Alcohol and Temozolomide Cancers (Basel). 2024 Feb 26; 16(5). . View in PubMed
  • NEO212, temozolomide conjugated to NEO100, exerts superior therapeutic activity over temozolomide in preclinical chemoradiation models of glioblastoma Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae095. . View in PubMed
  • Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate Autophagy. 2023 12; 19(12):3169-3188. . View in PubMed
  • Enhanced brain entry of checkpoint-inhibitory therapeutic antibodies facilitated by intraarterial NEO100 in mouse models of brain-localized malignancies J Neurosurg. 2023 09 01; 139(3):822-830. . View in PubMed
  • NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity Cancers (Basel). 2022 Dec 09; 14(24). . View in PubMed
  • Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia Cancers (Basel). 2021 Jul 06; 13(14). . View in PubMed
  • Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas PLoS One. 2020; 15(9):e0238238. . View in PubMed
  • Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro Ther Adv Med Oncol. 2019; 11:1758835919891567. . View in PubMed
  • A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice Molecules. 2018 Nov 08; 23(11). . View in PubMed
  • Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo Cancers (Basel). 2018 Sep 28; 10(10). . View in PubMed
  • Multimeric disintegrin protein polymer fusions that target tumor vasculature Biomacromolecules. 2014 Jul 14; 15(7):2347-58. . View in PubMed
  • Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential Toxicon. 2012 Mar 15; 59(4):472-86. . View in PubMed
  • Vicrostatin – an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities PLoS One. 2010 Jun 03; 5(6):e10929. . View in PubMed
  • The use of pepsin in receptor internalization assays Biochem Biophys Res Commun. 2009 Oct 16; 388(2):240-6. . View in PubMed
  • Development of a novel recombinant disintegrin, contortrostatin, as an effective anti-tumor and anti-angiogenic agent Pathophysiol Haemost Thromb. 2005; 34(4-5):177-83. . View in PubMed
  • Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression Mol Cancer Ther. 2004 Apr; 3(4):499-511. . View in PubMed